Ascend Capital’s Eli Lilly LLY Stock Holding History

Ascend Capital’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$5.37M	Buy	+50,000	New	+$5M	0.27%	96
2016 Q4	–	Sell	-334,449	Closed	-$26.8M	–	157
2016 Q3	$26.8M	Buy	+334,449	New	+$26.8M	1.64%	13
2014 Q2	–	Sell	-264,130	Closed	-$15.5M	–	200
2014 Q1	$15.5M	Sell	264,130 -254,984	-49%	-$14.2M	0.4%	76
2013 Q4	$26.5M	Buy	519,114 +439,114	+549%	+$22M	0.81%	42
2013 Q3	$4.03M	Sell	80,000 -598,580	-88%	-$31.3M	0.15%	149
2013 Q2	$33.3M	Buy	+678,580	New	+$36.9M	1.42%	16

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ascend Capital's LLY Position: Q3 2018 in Review

Ascend Capital opened a new position in Eli Lilly (LLY) in Q3 2018: 50,000 shares worth $5.37M. The stake represents 0.27% of the portfolio and ranks #96 among its holdings. This is a return to the name: Ascend Capital previously reported a position in LLY as recently as Q3 2016.

Ascend Capital first reported a position in LLY in Q2 2013 and has held it in 6 quarters since. The position peaked at $33.3M in Q2 2013. 1,431 funds tracked by Wall St. Rank hold LLY as of Q3 2018.

Ascend Capital held 50,000 shares of Eli Lilly worth $5.37M as of Q3 2018.
Eli Lilly was a new Ascend Capital position in Q3 2018.
Eli Lilly made up 0.27% of Ascend Capital's portfolio in Q3 2018, its #96 holding.
Ascend Capital first reported a position in Eli Lilly in Q2 2013 and has held it in 6 quarters since.
Ascend Capital's Eli Lilly position peaked at $33.3M in Q2 2013.
1,431 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.